21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning policy to expand the use of biosimilar medicines under the province's public drug plans.
New Brunswick's new biosimilar policy is expected to save the province more than $10 million annually when fully implemented, which will be reinvested to support coverage of new therapies.